RIN-PH-202: An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE OL)
The purpose of this study is to evaluate the safety and efficacy of inhaled treprostinil in patients with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE).
Must have previously participated in study RIN-PH-201.
The purpose of this study is to provide or continue to provide inhaled treprostinil to subjects who completed RIN-PH-201.
- IRB Number: 1602009433
- Research Study Identifier: TX6184
- Principal Investigator: William Harvey, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required